Literature DB >> 27573558

Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.

H Bertz1, M Lübbert1, K Ohneberg2, R Zeiser1, R Wäsch1, R Marks1, J Finke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27573558     DOI： 10.1038/leu.2016.248

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

Authors:  Sergio Amadori; Stefan Suciu; Roberto Stasi; Helmut R Salih; Dominik Selleslag; Petra Muus; Paolo De Fabritiis; Adriano Venditti; Anthony D Ho; Michael Lübbert; Xavier Thomas; Roberto Latagliata; Constantijn J M Halkes; Franca Falzetti; Domenico Magro; José E Guimaraes; Zwi Berneman; Giorgina Specchia; Matthias Karrasch; Paola Fazi; Marco Vignetti; Roel Willemze; Theo de Witte; Jean-Pierre Marie
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

2.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 3.  Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.

Authors:  Nicolaus Kröger
Journal:  Blood       Date:  2012-04-13       Impact factor: 22.113

4.  Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

Authors:  Patrice Chevallier; Richard M Szydlo; Didier Blaise; Reza Tabrizi; Mauricette Michallet; Madalina Uzunov; Nathalie Fegueux; François Guilhot; Simona Lapusan; Nicole Gratecos; Jean-Yves Cahn; Gerard Socié; Ibrahim Yakoub-Agha; Anne Huynh; Sylvie Francois; Jacques-Olivier Bay; Sébastien Maury; Agnes Buzyn; Nathalie Contentin; Mohamad Mohty
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-23       Impact factor: 5.742

5.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

Authors:  Stefan Fröhling; Richard F Schlenk; Sabine Kayser; Martina Morhardt; Axel Benner; Konstanze Döhner; Hartmut Döhner
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

6.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

Authors:  R Martino; L de Wreede; M Fiocco; A van Biezen; P A von dem Borne; R-M Hamladji; L Volin; M Bornhäuser; M Robin; V Rocha; T de Witte; N Kröger; M Mohty
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

7.  A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.

Authors:  Hartmut Bertz; Alexandros Spyridonidis; Ralph Wäsch; Carsten Grüllich; Mathias Egger; Jürgen Finke
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-01       Impact factor: 5.742

8.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.

Authors:  Keith Wheatley; Cassandra L Brookes; Andrew J Howman; Anthony H Goldstone; Donald W Milligan; Archibald G Prentice; Anthony V Moorman; Alan K Burnett
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

9.  Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

Authors:  Steven M Devine; Kouros Owzar; William Blum; Flora Mulkey; Richard M Stone; Jack W Hsu; Richard E Champlin; Yi-Bin Chen; Ravi Vij; James Slack; Robert J Soiffer; Richard A Larson; Thomas C Shea; Vera Hars; Alexander B Sibley; Sergio Giralt; Shelly Carter; Mary M Horowitz; Charles Linker; Edwin P Alyea
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.

Authors:  Uwe Platzbecker; Johannes Schetelig; Jürgen Finke; Rudolf Trenschel; Bart L Scott; Guido Kobbe; Kerstin Schaefer-Eckart; Martin Bornhäuser; Raphael Itzykson; Ulrich Germing; Dietrich Beelen; Gerhard Ehninger; Pierre Fenaux; H Joachim Deeg; Lionel Adès
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-11       Impact factor: 5.742
View more
  1 in total

1.  Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.

Authors:  Jesús Duque-Afonso; Gabriele Ihorst; Miguel Waterhouse; Robert Zeiser; Ralph Wäsch; Hartmut Bertz; Mehtap Yücel; Thomas Köhler; Joachim Müller-Quernheim; Reinhard Marks; Jürgen Finke
Journal:  Bone Marrow Transplant       Date:  2020-06-26       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.